1,778 results on '"Preudhomme, Claude"'
Search Results
152. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
153. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
154. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma
155. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations
156. Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules
157. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors
158. Biologie moléculaire des syndromes myélodysplasiques
159. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
160. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy
161. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.
162. Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab
163. Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study
164. Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL
165. Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes
166. Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia
167. Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study
168. The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy
169. Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
170. Tetraspanin CD81 Supports Cancer Stem Cell Function and Represents a Therapeutic Vulnerability in Acute Myeloid Leukemia
171. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
172. Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines
173. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
174. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
175. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA
176. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
177. Prognostic impact of RUNX1mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group
178. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy
179. Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias
180. Characterisation of Asp669Tyr Piezo1 cation channel activity in red blood cells: an unexpected phenotype
181. The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
182. Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications
183. Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults
184. Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia
185. Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia
186. Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia
187. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
188. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients
189. Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro
190. Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia
191. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study
192. Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
193. The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies
194. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia
195. Outcome of older patients with acute myeloid leukemia in first relapse
196. Quantification of JAK2V617F mutation by next-generation sequencing technology
197. Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia
198. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2and DDX41
199. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
200. Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.